Observational Study on the Effectiveness of Treatment with the GLP1-Receptor Agonist Dulaglutide in Patients with Type 2 Diabetes Mellitus: Real-Life Study in Spain
CURRENT RESEARCH IN DIABETES & OBESITY JOURNAL JUNIPER PUBLISHERS Authored by Amelia Oleaga Abstract Dulaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used in the treatment of Type 2 Diabetes Mellitus which has been shown to be effective in reducing HbA1c and weight with a high degree of safety. Aims: To evaluate the effectiveness of 1.5mg weekly dulaglutide under condition of routine clinical practice. The safety and discontinuation rate and its cause were quantified. The results obtained were compared with those published in randomised clinical trials and other observational studies. Subjects and Methods: 208 patients were included in this study, mean age was 62 years, BMI 35.7kg/m2 and HbA1c was 8.48%. Results: The results showed a statistically significant reduction in HbA1c of -0.95% and in mean weight of -4.63Kg after 24 months follow-up. The drug’s effect was lower in patients who had received previous treatment with another GLP-1RA, and in pati